Clinical Trials Logo

Clinical Trial Summary

This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To test for the equivalency of the two aspirin schedules. SECONDARY OBJECTIVES: I. To evaluate the effects of aspirin treatments on: Ia. The ratio of cell proliferation (Ki-67)/apoptosis (TUNEL) in rectal biopsies; Ib. The ratio of cell proliferation (Ki-67)/necroptosis (pMLKL) in rectal biopsies; Ic. Fecal occult blood test (measures of adverse events) as measured by stool samples. EXPLORATORY OBJECTIVES: I. To evaluate the effects of aspirin treatments on: Ia. Cyclooxygenase-2 (COX-2) in rectal biopsies; Ib. Bcl-2-like protein 4 (BAX) in rectal biopsies; Ic. Transient receptor potential cation channel subfamily M member (7TRPM7) in rectal biopsies; Id. Joint index of COX-2 with TRPM7 expression in rectal biopsies; Ie. Joint index of TRPM7 with BAX in rectal biopsies; If. Methylation assays using the MethylationEPIC BeadChip to identify methylation biomarkers in genes (i.e. CDKN2A [cell cycle regulation], MGMT [deoxyribonucleic acid (DNA) repair], DAPK1 [apoptosis], CDH1 [cell invasion], WNT16 [Wnt pathway] and RASSF1 [RAS signaling]) involved in colorectal carcinogenesis, and other epigenome-wide methylation biomarkers as measured in rectal biopsies; Ig. Metagenomics analysis to measure abundance of Escherichia coli (E. coli) and Fusobacterium and other microbiota in rectal swabs. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive aspirin orally (PO) daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial. ARM II: Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial. ARM III: Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial. After completion of study, patients are followed up at 1 month. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02965703
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 16, 2018
Completion date July 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT04516785 - Reducing Colonoscopies in Patients Without Significant Bowel Disease
Recruiting NCT05381792 - Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia
Withdrawn NCT05606081 - Predicting Risk for Post-polypectomy Colorectal Cancer N/A
Recruiting NCT05576506 - Application of Hyperspectral Imaging Analysis Technology in the Diagnosis of Colorectal Cancer Based on Colonoscopic Biopsy
Active, not recruiting NCT03796884 - Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Phase 2
Completed NCT05508503 - A Study on a Blood-based Dual-target Test for CRC Detection
Recruiting NCT02935049 - Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique N/A
Completed NCT05477836 - Feasibility and Safety of MiWEndo-assisted Colonoscopy N/A
Active, not recruiting NCT05740137 - Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy N/A
Active, not recruiting NCT05754229 - Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy N/A
Completed NCT03234725 - Analysis of New Endoscopic Features and Variable Stiffness in Colonoscopy: Prospective Randomised Trial
Completed NCT05913453 - Technical Failure During Colorectal Endoscopic Full Thickness Resection (EFTR): The "Through Thick and Thin" Study
Recruiting NCT05261932 - Research on Endoscopic Precision Biopsy.
Completed NCT02521727 - To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas
Completed NCT02226185 - Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence Phase 2/Phase 3
Completed NCT00298545 - Effect of Vitamin D and Calcium on Genes in the Colon Phase 1
Completed NCT03268655 - Ginger and Gut Microbiome (GINGER) N/A
Active, not recruiting NCT04952129 - Optimal Selenium for Bowel Polyps (OSCAR) Phase 1
Recruiting NCT04444908 - Development and Validation of an Artificial Intelligence-assisted Strategy Selection System for Colonoscopy Cleaning